Awardees

Canice Christian
July 1, 2026 – June 30, 2027
Designing climate adaptive strategies to mitigate the impact of extreme weather events on tuberculosis treatment and prevention in Zimbabwe
Amount: $40,000.00

Josephine Reijneveld
July 1, 2026 – June 30, 2027
High-throughput CRISPR knockout screen in human primary myeloid cells to uncover novel host directed therapy targets for Tuberculosis treatment
Amount: $40,000.00

Mark Warden
July 1, 2026 – June 30, 2027
The RS ratio as a novel treatment response biomarker in pediatric pulmonary tuberculosis in Kampala, Uganda
Amount: $40,000.00 (UCSF Center for Tuberculosis ($20,000) and Institute for Global Health and Sciences ($20,000))

Mollie Hudson
March 1, 2026 – February 28, 2027
Cost and cost-effectiveness of the Bolsa Familia Program for reducing tuberculosis incidence and mortality
Amount: $40,000 (UCSF Center for Tuberculosis ($35,000) and Institute for Global Health and Sciences ($5,000))

Ada Kwan
February 1, 2026 – January 31, 2027
Variations in Provider Knowledge under California's Tuberculosis Prevention Policy (KNOW-TB)
Amount: $40,000.00

Hemant Joshi
February 1, 2026 – January 31, 2027
Unlocking the Potential of Novel Streptogramins for Tuberculosis Treatment: In vivo Efficacy and Mechanistic Structural Investigations
Amount: $40,000 (UCSF Center for Tuberculosis ($35,000) and Institute for Global Health and Sciences ($5,000))

Nora West
August 1, 2025 – January 31, 2027
Addressing an unmet need: piloting Problem Management Plus among people with TB
Amount: $40,000.00

Christopher Rae
August 1, 2024 – July 31, 2025
Testing the role of newly discovered components of an M. tuberculosis multiprotein efflux pump in virulence and antibiotic susceptibility
Amount: $40,000 

Paul Ogongo 
August 1, 2024 – July 31, 2025 
T cell responses induced by two-dose BCG vaccination in BCG-naïve healthy adults in the United States 
Amount: $40,000.00

Martineau Louine 
August 1, 2024 – July 31, 2025
Host Response to Tuberculous Meningitis and Correlation with Clinical Outcomes
Amount: $40,000 

Weihao Zheng
February 1, 2024 – May 31, 2025
Epitranscriptomic regulation of Mycobacterium tuberculosis infection in macrophages
Amount: $40,000 

Suzanne Dufault
February 1, 2024 – June 30, 2025
Identifying the Optimal Durations of TB Therapeutics: Implementing Candidate Dose-Ranging Methods to Efficiently Model the Treatment Duration-Response Curve
Amount: $40,000 

Jonathan Budzik
February 1, 2024 – January 31, 2025
Determining the Mechanism of M. tuberculosis Growth Restriction in TAX1BP1-deficient alveolar macrophages
Amount: $40,000 

Mohamad Dandan  
February 1, 2024 – June 30, 2025
How does kasugamycin inhibit protein translation initiation in a context-specific fashion in Mycobacterium tuberculosis?
Amount: $80,000  

Rania Bouzeyen
August 1, 2023 – July 31, 2024
Development of therapeutic antibodies for tuberculosis
Amount: $40,000 

Alex Mohapatra
August 1, 2023 – January 31, 2025
Impact of Mycobacterium tuberculosis on monocyte differentiation in vivo
Amount: $40,000.00 

Ashley Wolf
August 1, 2023 – July 31, 2024
The role of the gut microbiome in susceptibility to Mycobacterium tuberculosis
Amount: $40,000.00

Alex Eskandarian
August 1, 2022 – January 31, 2024
Characterizing mechanical morphotype switching as an adaptive response in Mycobacterium tuberculosis
Amount: $40,000.00

Marjorie Imperial
February 1, 2022 – January 31, 2023
Assessing predictors of poor post TB outcomes: A cohort study of Ugandan TB patients
Amount: $40,000.00

Sophie Huddart
February 1, 2022 – January 31, 2023 (NCE through December 31, 2023)
Development of evidence-based tools to support innovation in TB clinical trial design
Amount: $40,000.00

Matthew Kutys
July 1, 2021 – June 30, 2022
Optimization and investigation of a three-dimensional human biomimetic model of vascularized tuberculosis granuloma
Amount: $40,000.00 

Jeff Whitman
August 1, 2024 – July 31, 2025
Improving Antituberculosis Drug Monitoring for Personalized Medicine
Amount: $40,000.00